mRNA COVID-19疫苗接种后心肌炎和/或心包炎风险:加拿大BNT162b2与mRNA-1273疫苗的头对头比较
该研究基于加拿大免疫接种后不良事件监测系统2020年12月至2022年3月的报告,比较BNT162b2与mRNA-1273疫苗接种后心肌炎和/或心包炎的风险。在18-29岁男性第二剂接种者中,mRNA-1273接种者(n=106)的心肌炎和/或心包炎归因风险是BNT162b2接种者(n=33)的5.69倍(95%CI:4.07-7.95;p<0.001)。泊松回归模型估计,该组接种mRNA-1273后风险是BNT162b2的4.72倍(p<0.001)。结论认为18-39岁人群接种mRNA-1273后心肌炎和/或心包炎风险高于BNT162b2,尤其是18-29岁男性风险高出数倍。
要点
- 18-29岁男性第二剂接种mRNA-1273者心肌炎和/或心包炎归因风险是BNT162b2者的5.69倍(95%CI:4.07-7.95;p<0.001)。
- 泊松回归模型估计同组接种mRNA-1273后风险是BNT162b2的4.72倍(p<0.001)。
- 18-39岁人群接种mRNA-1273后心肌炎和/或心包炎风险高于BNT162b2,尤其18-29岁男性风险高出数倍。
核心结论
- 在18-39岁人群中,接种mRNA-1273后心肌炎和/或心包炎风险高于接种BNT162b2,尤其是18-29岁男性风险高出数倍。
研究设计与样本
- 基于加拿大免疫接种后不良事件监测系统2020年12月至2022年3月报告计算心肌炎和/或心包炎报告率。
- 对18-39岁个体,以2015至2019年背景率比较,估计每种疫苗的额外病例和归因发病率。
- 头对头比较采用泊松回归,以疫苗接种周为条件,按年龄和性别及总体估计接种mRNA-1273后一周相对于接种BNT162b2后一周的率比。
- 分析限制在2021年5月30日至2021年3月13日(原文此处日期表述有矛盾),此时媒体关注度升高不太可能对两种产品的报告率产生不同影响。
主要发现
- 在18-29岁男性第二剂mRNA COVID-19疫苗接种者中,mRNA-1273接种者(n=106)的心肌炎和/或心包炎归因风险是BNT162b2接种者(n=33)的5.69倍(95%CI:4.07-7.95;p<0.001)。
- 同组中,泊松回归模型估计接种mRNA-1273后心肌炎和/或心包炎风险是接种BNT162b2后的4.72倍(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Canadian and international data suggest the risk of myocarditis and/or pericarditis is elevated during the week after mRNA COVID-19 vaccination, particularly in younger age groups, in males, and after second doses. OBJECTIVES: This article examines whether there is a product-specific difference in the risk for myocarditis and/or pericarditis between the two mRNA vaccines administered in Canada: BNT162b2 (Pfizer-BioNTech Comirnaty) and mRNA-1273 (Moderna Spikevax). MATERIALS AND METHODS: Reporting rates of myocarditis and/or pericarditis were calculated from reports received by the Canadian Adverse Events Following Immunization Surveillance System from December 2020-March 2022. Excess cases and attributable incidence among individuals aged 18-39 were estimated for each vaccine in comparison with background rates from 2015 to 2019. Head-to-head comparisons used Poisson regression, conditioned on week of vaccine administration, to estimate rate ratios for the week after mRNA-1273 vaccination versus the week after BNT162b2, by age and sex as well as overall. Analyses were restricted to May 30-March 13, 2021, when heightened media awareness was unlikely to have affected reporting rates for the two products differentially. RESULTS: In 18-29 year-old males who received a second dose of mRNA COVID-19 vaccine, attributable risk of myocarditis and/or pericarditis was found to be 5.69 (95% CI: 4.07 - 7.95; p < 0.001) times higher among mRNA-1273 recipients (n = 106) as compared to BNT162b2 recipients (n = 33). In the same group, Poisson regression modelling estimated that the risk of myocarditis and/or pericarditis was 4.72 (p-value = <0.001) times higher after mRNA-1723 compared to BNT162b2 vaccination. CONCLUSIONS: The risk of myocarditis and/or pericarditis is higher after mRNA-1723 vaccination than BNT162b2 vaccination in those aged 18-39 years, especially in males aged 18-29 years, where the risk is several times higher.
引用
- Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022. PMID: 35750537. doi:10.1016/j.vaccine.2022.05.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。